Board to mull bonus share; 100% dividend & business expansion proposals next week: Gujarat-based penny stock under Rs 2 hit upper circuit; 1:2 stock split on June 11

The stock is trading at 0.90 times its book value and the stock is up by 87.5 per cent from its 52-week low of Rs 1.04 per share.

On Tuesday, shares of Murae Organisor Limited (Formerly known as Earum Pharmaceuticals Limited) hit a 5 per cent upper circuit to Rs 1.95 per share from its previous closing of Rs 1.86 per share. The stock’s 52-week high is Rs 2.73 per share and its 52-week low is Rs 1.04 per share. This penny stock under Rs 2 has been hitting consecutive 8 upper circuits.

The company informed that a meeting of the Board of Directors of MURAE Organisor Ltd is scheduled to be held on Thursday, June 13, 2025, at the registered office of the Company, inter alia, to consider and discuss the following business items:

1. To consider and approve the declaration of dividend of up to 100 per cent of the face value of equity shares of the company for the financial year ended March 31, 2025, subject to shareholders’ approval, if applicable.
2. To consider and approve a bonus issue of equity shares to the shareholders of the company, subject to necessary approvals and compliances.
3. To consider strategic business expansion proposals, including capital deployment for proposed and ongoing projects in the agro and distillery sectors.
4. To transact any other business with the permission of the chair as may be deemed necessary in the interest of the company.

The company's Board of Directors approved a 1:2 stock split, effective June 11, 2025. This means each Rs 2 face value share will split into two Rs 1 face value shares. The goal is to increase liquidity and make shares more accessible to retail investors. The total share capital remains unchanged at Rs 1,85,89,64,310, but the number of shares doubles from 9,29,48,21,55 to 1,85,89,64,310.

About the Company

Murae Organisor Ltd., incorporated in 2012, operates within the pharmaceutical industry, focusing on the marketing, trading, and distribution of a diverse range of pharmaceutical formulations. The company markets over 120 products under its brand names, such as HYGNEX+, Erolon, and Calcybar, while outsourcing its manufacturing to third-party facilities. In addition to their branded products, Murae also trades in active pharmaceutical ingredients. Their product portfolio spans various therapeutic categories, including antibiotics, antimalarials, antihistamines, analgesics, dermatology products, neurological drugs, gastrointestinal drugs, and various supplements like calcium and multivitamins. Murae maintains an international presence, exporting to more than 15 countries across North America, CIS, Latin America, Africa, and Southeast Asia, with over 60 international products currently under registration.

According to Quarterly Results, the net sales increased by 59,845 per cent to Rs 515.53 crore and net profit increased by 144 per cent to Rs 2.85 crore in Q4FY25 compared to Q4FY24. In its annual results, the net sales increased by 33,554 per cent to Rs 854.82 crore and net profit increased by 14,940 per cent to Rs 7.52 crore in FY25 compared to FY24

The company has a market cap of Rs 181.25 crore and its 100 per cent stake is owned by public shareholders. The stock is trading at 0.90 times its book value and the stock is up by 87.5 per cent from its 52-week low of Rs 1.04 per share.

Disclaimer: The article is for informational purposes only and not investment advice.